Jardiance is owned by Boehringer Ingelheim.

Jardiance contains Empagliflozin.

Jardiance has a total of 18 drug patents out of which 0 drug patents have expired.

Jardiance was authorised for market use on 01 August, 2014.

Jardiance is available in tablet;oral dosage forms.

Jardiance can be used as method for reducing the risk of cardiovascular death and hospitalization in patients with heart failure by administration of empagliflozin, method of treating type 2 diabetes mellitus in a patient with renal impairment (30 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin, treating type 2 diabetes mellitus by assessing renal function and orally administering empagliflozin in a daily amount of 10 mg or 25 mg if the egfr>=45 ml/min/1.73 m2 and <60 ml/min/1.73 m2, wherein the treatment improves glycemic control, treatment and reduction of risk by administration of empagliflozin to adults with chronic kidney disease at risk of progression, method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin and metformin, method of reducing the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and cardiovascular disease by once daily administration of 10 mg or 25 mg of empagliflozin, method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin, method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin.

Drug patent challenges can be filed against Jardiance from 20 December, 2025.

The generics of Jardiance are possible to be released after 11 December, 2034.